Extended Data Fig. 8: REGN5381 leads to a reduction of NTproANP in normotensive non-human primates.
From: Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone
Normotensive cynomolgus monkeys received a single intravenous bolus of saline/vehicle (n = 5; black circles) or REGN5381 subcutaneous (n = 5; 1 mg/kg [pink line]), (n = 5; 5 mg/kg [pale yellow line]), (n = 5; 25 mg/kg [red line]) or intravenous (n = 5; 5 mg/kg [light blue line]) or (n = 5; 25 mg/kg [dark blue line]). Serum NTproANP levels were measured throughout the study. Data are mean ± SEM. Statistical Analysis: RM 2-Way ANOVA or 1-Way ANOVA; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. ANOVA, analysis of variance; NTproANP, N-terminal proatrial natriuretic peptide; RM, repeated measures; SEM, standard error of mean; Tx, treatment.
